- Home
- FOLD vs BL Comparison
FOLD vs BL Comparison
Compare FOLD & BL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FOLD
- BL
- Stock Information
- Founded
- FOLD 2002
- BL 2001
- Country
- FOLD United States
- BL United States
- Employees
- FOLD N/A
- BL N/A
- Industry
- FOLD Biotechnology: Pharmaceutical Preparations
- BL Computer Software: Prepackaged Software
- Sector
- FOLD Health Care
- BL Technology
- Exchange
- FOLD Nasdaq
- BL Nasdaq
- Market Cap
- FOLD 2.9B
- BL 3.1B
- IPO Year
- FOLD 2007
- BL 2016
- Fundamental
- Price
- FOLD $6.83
- BL $44.44
- Analyst Decision
- FOLD Strong Buy
- BL Buy
- Analyst Count
- FOLD 9
- BL 12
- Target Price
- FOLD $17.00
- BL $61.00
- AVG Volume (30 Days)
- FOLD 3.9M
- BL 808.3K
- Earning Date
- FOLD 05-08-2025
- BL 05-06-2025
- Dividend Yield
- FOLD N/A
- BL N/A
- EPS Growth
- FOLD N/A
- BL 78.84
- EPS
- FOLD N/A
- BL 1.45
- Revenue
- FOLD $528,294,999.00
- BL $653,336,000.00
- Revenue This Year
- FOLD $21.83
- BL $10.56
- Revenue Next Year
- FOLD $22.16
- BL $9.42
- P/E Ratio
- FOLD N/A
- BL $30.58
- Revenue Growth
- FOLD 32.29
- BL 10.74
- 52 Week Low
- FOLD $6.20
- BL $40.82
- 52 Week High
- FOLD $12.65
- BL $66.25
- Technical
- Relative Strength Index (RSI)
- FOLD 32.01
- BL 37.81
- Support Level
- FOLD $6.20
- BL $41.00
- Resistance Level
- FOLD $6.95
- BL $46.37
- Average True Range (ATR)
- FOLD 0.43
- BL 2.09
- MACD
- FOLD -0.04
- BL 0.01
- Stochastic Oscillator
- FOLD 29.86
- BL 39.89
About FOLD Amicus Therapeutics Inc.
Amicus Therapeutics Inc is a biotechnology company focused on discovering, developing and delivering medicines for people living with rare metabolic diseases. The company is engaged in developing a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of advanced therapies to treat a range of devastating rare and orphan diseases.
About BL BlackLine Inc.
BlackLine Inc is engaged in providing financial accounting close solutions delivered as Software as a Service (SaaS). The Company's solutions enable its customers to address various aspects of their financial close process including account reconciliations, variance analysis of account balances, journal entry capabilities, and certain types of data matching capabilities. The majority of the revenue of the company is earned in the United States.